Ubrogepant Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 50 mg, 100 mg

Reference Brands: Ubrelvy (USA/India)

Category: Neurology

Ubrogepant is available in Tablets and strengths such as 50 mg, 100 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ubrogepant is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Ubrogepant can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Ubrogepant is an advanced oral medication developed for the acute treatment of migraine, a neurological disorder that can significantly affect daily functioning, productivity, and quality of life. It belongs to the class of calcitonin gene-related peptide (CGRP) receptor antagonists, a newer group of therapies that specifically target pathways involved in migraine attacks. CGRP plays a crucial role in the development of migraine by promoting inflammation and pain signaling in the nervous system. By blocking the CGRP receptor, ubrogepant helps reduce headache intensity and associated symptoms such as nausea, light sensitivity, and sound sensitivity during a migraine episode.

Unlike traditional migraine treatments such as triptans, ubrogepant does not cause vasoconstriction, making it a suitable option for patients who may have cardiovascular risk factors or cannot tolerate certain therapies. Clinical studies have shown that ubrogepant provides effective pain relief and improves functional recovery compared to placebo, with a generally favorable safety and tolerability profile. The most commonly reported side effects are mild, including nausea, dizziness, and somnolence.

Ubrogepant represents an important advancement in migraine management due to its targeted mechanism of action, convenient oral administration, and rapid onset of effect. While it offers significant benefits, it should be used with caution in patients with certain conditions such as severe hepatic impairment or when taken with strong CYP3A4 inhibitors. Overall, ubrogepant provides a modern and effective therapeutic option for the acute treatment of migraine in adults.